Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8TCG1
UPID:
CIP2A_HUMAN
Alternative names:
Cancerous inhibitor of PP2A; p90 autoantigen
Alternative UPACC:
Q8TCG1; A1L4J7; B9EGC3; Q6P4G6; Q8WVP8; Q96PI2; Q9H9C6; Q9P204
Background:
Protein CIP2A, also known as Cancerous inhibitor of PP2A and p90 autoantigen, plays a pivotal role in human malignancies. It functions as an oncoprotein by inhibiting PP2A and stabilizing MYC, which are crucial processes in the development and progression of cancer. This protein promotes anchorage-independent cell growth and tumor formation, highlighting its significance in oncogenesis.
Therapeutic significance:
Understanding the role of Protein CIP2A could open doors to potential therapeutic strategies. Its critical involvement in inhibiting PP2A and stabilizing MYC in cancer makes it a promising target for drug discovery efforts aimed at developing novel cancer therapies.